Andreas Baumbach
PCRonline Editorial Board Advisor
The research in interventional cardiology focuses on improving outcomes of patients treated for acute coronary syndromes. This includes the use of novel interventional devices, the assessment of new medication during and after procedures. My interest lies in minimising the size of the heart attack and also minimising the side effects of medication used adjunctively during acute procedures. In the field of percutaneous valve implantation, I lead the pivotal trial on embolic protection during transcatheter aortic valve implantation. This technology might help to reduce the reate of stroke and subclinical cerebral infarcts during the procedure.
ACTIVITIES
- EAPCI Past-President
- Chair for Device Innovation at the Queen Mary University of London, United Kingdom since 2017.
- Director of Interventional Research, Barts Heart Centre, London - United Kingdom since 2017.
- Consultant Cardiologist at Bristol Heart Institute between 2000-2016.
Declaration of interest
| Function | Company |
|---|---|
| Other | Medtronic |
| Grants/research support | Terumo |
| Grants/research support | The Medicines Company |
Latest contributions
Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...
EAPCI Fellowship Grant Awards
21 May 2025 – From EuroPCR 2025
Celebrate the achievements of emerging cardiology leaders with the EAPCI Fellowship Grant Awards session. This presentation highlights the awarded fellows' contributions and the impact of fellowship support on advancing interventional cardiology research and clinical practice.
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
Complex multivessel disease - LIVE Case
21 May 2025 – From EuroPCR 2025
An 89-year-old male patient presented with stable angina, preserved LV function and some risk factors such as hypertension and diabetes. CT scan and angiography revealed occlusion of proximal RCA and bifurcation lesions on LAD and circumflex (medina 1,1,1). Operators treated the bifurcation lesions with provisional stenting.
Regarding...
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Focus on drug coated balloons: evidence and practice
07 Jan 2025
This Special Report led by Andreas Baumbach explores the history, current techniques, evidence, and future of DCBs, plus insights on left main stent restenosis.
Best of science and education in cardiovascular interventional medicine in 2024
16 Dec 2024
Dear Colleagues, dear PCR Companions,
As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.
2024 was a record year...
Editorial: Focus on Drug-Coated Balloons (DCB) in clinical practice
19 Dec 2024
DCBs have undergone extensive development to meet the challenges of minimizing restenosis and maintaining vessel patency. Unlike stents, DCBs deliver an antiproliferative drug directly to the arterial wall without leaving a permanent implant. This approach has proven effective in treating small-vessel disease, in-stent restenosis, and de...
Author
TAVI for pure aortic regurgitation with a dedicated CE-mark device: an underdiagnosed and undertreated disease
26 Nov 2024 – From PCR London Valves 2024
Explore this session to learn about the unmet needs in aortic regurgitation (AR) and the performance of dedicated TAVI devices for AR. Discover why new thresholds for severe AR are necessary, and how traditional methods may underestimate its severity. Gain insights into the TRILOGY THV system,...
TAVI for pure aortic regurgitation - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on aortic regurgitation:
- An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
Align for the future with Myval THV series - From randomised trials to everyday clinical practice
25 Nov 2024 – From PCR London Valves 2024
Through the presentation of several compelling cases, including an 88-year-old male with CKD, RBBB, moderate LV dysfunction, and severe aortic stenosis, a Type 1a bicuspid native AS, and an extraordinary TAVI in an 83-year-old with acute heart failure and comorbidities, this session will dive into the...
TAVI for aortic regurgitation
25 Nov 2024 – From PCR London Valves 2024
Curious about advancing your knowledge in TAVI for aortic regurgitation? Don’t miss this video!
You'll dive into the diagnostic and treatment strategies to optimize outcomes in patients with aortic regurgitation, explore groundbreaking technologies like the Jenavalve Trilogy THV system and gain insights from the latest clinical evidence and...
TAVI innovations: latest breakthroughs from PCR London Valves 2024
24 Nov 2024 – From PCR London Valves 2024
Curious about the latest advancements shaping the future of TAVI? Don't miss this video which deliver insights from the PCR London Valves 2024 Late-Breaking Trials, diving into key topics that matter most in clinical practice.
Explore 5-year outcomes of AVR in low-risk patients stratified by annulus size,...
Rendez-vous with Myval THV series and Landmark RCT subset analysis
24 Nov 2024 – From PCR London Valves 2024
Discover this interactive session during which the audience learns about and discusses the novel Myval THV Series, a series of valves featuring intermediate and XL sizes. They also discuss the results of the pivotal LANDMARK randomized controlled trial and its relevance in clinical practice.
DCB digital crosstalk: practice patterns for patients with diabetes and diffuse disease in Asia
16 Oct 2024
Watch the replay of this webinar on the concept of DCB in native vessel disease and so much more!
DCB digital crosstalk: practice patterns for patients with diabetes and diffuse disease in Europe
07 Oct 2024
Watch the replay of this webinar on the concept of DCB in native vessel disease and so much more!
A patient with ISR: what is the role of DCB today?
07 Oct 2024
Watch the replay of this webinar to review the mechanisms of ISR and so much more!
TAVI for a patient with small aortic annulus
04 Oct 2024 – From AICT-AsiaPCR 2024
Join us for a LIVE educational case from the National University Heart Centre, Singapore, focusing on the challenges of TAVI in patients with small aortic annuli. Gain insights into strategies for valve selection, deployment techniques, and overcoming anatomical constraints to deliver optimal outcomes for this complex...
Drug-coated balloons as a first choice for patients with de novo lesions: pros and cons
25 Sep 2024
Watch the replay of this webinar about the concept of DCB in native vessel disease and so much more!
The LANDMARK RCT: key findings and relevance in clinical practice
15 May 2024 – From EuroPCR 2024
Join Patrick Serruys, Niels Van Royen, and Andreas Baumbach in a roundtable discussing the LANDMARK RCT trial, a randomized comparison of three valves aiming to validate the Myval balloon-expandable THV. Explore the trial's methodology, clinical outcomes, and findings on this new intermediate-size device, which offers adaptability...
PCR Webinars: Bringing the hot topics in interventional cardiology to your home
10 Jun 2024
According to Medical Director of PCR Webinars, Dejan Milasinovic, two novel additions to the platform will increase the interactive experience and take webinar based learning to a new level.
Multivessel disease PCI guided by physiology and IVUS - LIVE case
16 May 2024 – From EuroPCR 2024
A 78-year-old woman with hypertension, dyslipidemia, and obesity, presented with angina CCS2 and preserved LV function. The coronary angiogram showed stenosis in the RCA (proximal and mid), CX, and calcified proximal and mid LAD involving D1 and D2.
The operators performed PCI on the RCA (1 stent)...
Align for the future with next-generation balloon expandable THV technology
15 May 2024 – From EuroPCR 2024
In this session, explore the next-generation balloon-expandable Myval Octacor THV, focusing on its key features, procedural impact, and potential clinical benefits. Understand the procedural steps for planning and implanting it, especially for intermediate and extra-large sizes, using the Octalign technique. Learn about the unmet clinical need...
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
Align for the future with next-generation balloon expandable transcatheter heart valve technology
14 May 2024 – From EuroPCR 2024
Tune in to this EuroPCR 2024 session to explore the Myval Octacor THV, a cutting-edge balloon-expandable transcatheter heart valve. Discover its advanced features, potential clinical benefits, and procedural impact. Learn about the latest updates on the Myval THV series and the LANDMARK RCT. Explore the OctaAlign technique for...
Bioresorbable scaffolds - back to the future? Pros and Cons
14 Mar 2024
Watch the replay of this webinar with E. Barbato, A. Baumbach and M. Sabate. Understand the evolution process of bioresorbable scaffold technology and much more.
TAVI and access: alternating is wise
16 Jan 2024 – From GulfPCR-GIM 2023
Given that 10-20% of patients have restricted or even impossible femoral access, it is important, for both procedural and patient safety, that alternative access is sometimes considered. Learn what options are available, whether surgical or transcatheter, depending on the patient, and how to put these choices into...
TAVI with a new generation of valve and difficult arterial access - LIVE case
07 Dec 2023 – From GulfPCR-GIM 2023
An 84-year-old woman with type 2 diabetes, anaemia (Hgb: 9 g/dl), morbid obesity and limited mobility, and mild LV function impairment (50%), presented an acute heart failure on severe aortic valve stenosis.
The operators decided to implant an Evolut FX by femoral access with secondary access in...
